NEW YORK (GenomeWeb News) – Noninvasive prenatal test developer Natera has completed a $54.6 million financing round to support its expansion and the rollout of its sequencing-based fetal aneuploidy test called Panorama.

Two new investors, OrbiMed Advisors and Harmony Partners, and other new undisclosed investors joined the company's existing investors, Claremont Creek Ventures, Lightspeed Venture Partners, Founders Fund, and Sequoia Capital.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.